Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4178543 | 0.83 | MIF (0.44) | TDP1CYP3A4CYP1A2GABRA1GABRB2 | |
| SCHEMBL13359882 | 0.80 | CYP3A4 (0.38) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL26672083 | 0.75 | MAPK1 (0.40) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL10615043 | 0.74 | TDP1 (0.54) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL27873 | 0.74 | TDP1 (0.54) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL27621561 | 0.72 | TDP1 (0.52) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL11344825 | 0.71 | KMO (0.49) | MAPK1TDP1CYP3A4TRPA1 | |
| SCHEMBL22966418 | 0.71 | KMO (0.49) | MAPK1TDP1CYP3A4TRPA1 | |
| Ethylene SCHEMBL10425506 | 0.71 | TDP1 (0.50) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL59005 | 0.70 | MAPK1 (0.45) | MAPK1TDP1CYP3A4TRPA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20190336506-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | HIGH POINT PHARMACEUTICALS, LLC | 2019-11-07 | — | — | US | disclosed |
| US-10391097-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180360839-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | TRANSTECH PHARMA, INC. | 2018-12-20 | — | — | US | disclosed |
| US-10085990-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-20180071297-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | VTV THERAPEUTICS LLC | 2018-03-15 | — | — | US | disclosed |
| EP-1919465-B1 | GSK-3 INHIBITORS | ASD THERAPEUTICS PARTNERS LLC (US) | 2017-12-27 | — | — | EP | disclosed |
| US-9833457-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170252343-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | VTV THERAPEUTICS LLC | 2017-09-07 | — | — | US | disclosed |
| US-9687489-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | VTV THERAPEUTICS LLC (US) | 2017-06-27 | — | — | US | disclosed |
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PLEXXIKON, INC. | 2006-05-11 | — | — | US | disclosed |
| WO-2006026754-A9 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON INC (US) | 2006-04-20 | — | — | WO | disclosed |
| EP-1638941-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2006-03-29 | — | — | EP | disclosed |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | AVENTIS PHARMACEUTICALS INC. (US) | 2006-03-23 | — | — | US | disclosed |
| WO-2006026754-A2 | BICYCLIC HETEROARYL PDE4B INHIBITORS | PLEXXIKON, INC. (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1622610-A1 | 1-(2H-PYRAZOL-3-YL)-3- 4-[1-(BENZOYL)-PIPERIDIN-4-YLMETHYL]-PHENYL -UREA DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF INFLAMMATIONS | Aventis Pharmaceuticals Inc. (US) | 2006-02-08 | — | — | EP | disclosed |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABBVIE INC. | 2005-01-27 | — | — | US | disclosed |
| WO-2004113304-A1 | INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-12-29 | — | — | WO | disclosed |
| WO-2004100946-A1 | 1- (2H-PYRAZOL -3-YL) -3YL) {4-`1- (BENZOYL) -PIPERIDIN-4-YLMETHYL!-PHENYL}-UREA DERIVATIVES AND RELATED COMPOUNDS AS INHBITORS OF P38 KINASE AND/OR TNF INHIBITORS FOR THE TREATMENT OF IMFLAMMATIONS | AVENTIS PHARMACEUTICALS INC. (US) | 2004-11-25 | — | — | WO | disclosed |
| US-6689782-B2 | 3-PIPERAZINYL-2-DIARYLUREA-QUINAZOLINONE DERIVATIVES; POTENTIATORS OF ANTIFUNGAL AGENTS | ESSENTIAL THERAPEUTICS, INC. | 2004-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100218-A1 | Phosphodiesterase 4; asthma, chronic obstructive pulmonary disease, Alzheimer's disease, diffuse large-cell B cell lymphoma, and chronic lymphocytic leukemia; 8-[3-(3,4-dimethoxy-phenyl)-pyrrolo[2,3-b]pyridine-1-sulfonyl]-quinoline | PDE4B, PDE4A, PDE4C | MAPK1 2299/4885TDP1 37/4885CYP3A4 115/4885 |
| US-20190336506-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, PDE4B, TNF | MAPK1 954/4885TDP1 652/4885CYP3A4 124/4885 |
| US-20180360839-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | MAPK1 667/4885TDP1 621/4885CYP3A4 106/4885 |
| US-10568888-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | PDE4A, PDE4B, TNF | MAPK1 954/4885TDP1 652/4885CYP3A4 124/4885 |
| US-20050020603-A1 | Indazole, benzisoxazole, and benzisothiazole kinase inhibitors | ABL1, BLK, BTK | MAPK1 199/4885TDP1 2697/4885CYP3A4 793/4885 |
| US-20060063796-A1 | Pyrazoles as inhibitors of tumor necrosis factor | TNF, LITAF, MAPK1 | MAPK1 3/4885TDP1 1643/4885CYP3A4 281/4885 |
| US-20180071297-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | MAPK1 667/4885TDP1 621/4885CYP3A4 106/4885 |
| US-10085990-B2 | Tricyclic compounds as modulators of TNF-α synthesis and as PDE4 inhibitors | PDE4A, TNF, PDE4B | MAPK1 617/4885TDP1 744/4885CYP3A4 113/4885 |
| US-10391097-B2 | Tricyclic compounds as modulators of TNF-alpha synthesis and as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | MAPK1 667/4885TDP1 621/4885CYP3A4 106/4885 |
| US-20170252343-A1 | TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-ALPHA SYNTHESIS AND AS PDE4 INHIBITORS | TNF, PDE4A, PDE4B | MAPK1 626/4885TDP1 283/4885CYP3A4 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.